Recent Updates
Recently added Catalysts

Sulfadoxine-Pyrimethamine/Chloroquine

Phase 2

PLASMODIUM FALCIPARUM MALARIA | Small molecule | Infectious Disease |Pfizer, Inc.|Last Updated: May 10, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment230
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00074841Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in IndiaPHASE2 COMPLETED 230Sep 1, 2003Jan 1, 2005May 10, 20117 India
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
PurposeTREATMENT
Interventions
NameTypeDescription
Azithromycin/ChloroquineDRUG -
Sulfadoxine-Pyrimethamine/ChloroquineDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites7

INCLUSION CRITERIA: * Females and males \>=18 years of age with uncomplicated, symptomatic malaria as indicated by the presence of both of the following: a.) Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites/uL; b.) Fever or history of fever ( \>=38...

Countries:India
Unlock Eligibility Criteria